药物与急性闭角型青光眼的关联
该病例交叉研究利用韩国健康保险审查评估服务数据库,纳入2013至2019年首次诊断并治疗的13,531例急性闭角型青光眼患者,分析发病前1至180天处方药物。共识别61种与急性闭角型青光眼相关的药物,其中舒马普坦的比值比最高(OR 12.60),其次为托吡酯(OR 5.10)和度洛西汀(OR 4.04),并发现乳果糖和甲氧氯普胺等既往未认为相关的药物。
要点
- 61种药物与急性闭角型青光眼发生相关,舒马普坦OR 12.60、托吡酯OR 5.10、度洛西汀OR 4.04。
- 从处方到发病的中位时间(IQR)为11.9天(10.9-12.8)。
- 乳果糖(OR 2.81)和甲氧氯普胺(OR 2.52)等既往未认为相关的药物也被识别。
核心结论
- 病例交叉研究结果提示,对于服用所发现的61种与急性闭角型青光眼相关药物中任何一种的患者,需要考虑急性闭角型青光眼风险。
研究设计与样本
- 病例交叉研究,使用韩国健康保险审查评估服务数据库,该数据库包含全体韩国人口的医疗信息。
- 纳入2013至2019年间首次诊断并治疗的急性闭角型青光眼患者,通过诊断和操作代码识别。
- 共分析13,531例患者(平均[SD]年龄66.8[10.6]岁;9585例[70.8%]为女性)在发病前1至180天期间处方的949种药物。
- 对每例患者,发病前1至30天为危险期,发病前91至180天为对照期。
主要发现
- 共发现61种药物与急性闭角型青光眼相关。
- 舒马普坦与急性闭角型青光眼发生的比值比最高(OR 12.60 [95% CI 4.13-38.44]),其次为托吡酯(OR 5.10 [95% CI 2.22-11.70])和度洛西汀(OR 4.04 [95% CI 2.95-5.54])。
- 对于这61种药物,从处方到急性闭角型青光眼发病的中位(IQR)时间为11.9天(10.9-12.8)。
- 识别出多种既往未认为与急性闭角型青光眼相关的药物,包括乳果糖(OR 2.81 [95% CI 1.72-4.61])和甲氧氯普胺(OR 2.52 [95% CI 1.95-3.25])。
临床怎么用
- 作者认为,对于服用所发现的61种与急性闭角型青光眼相关药物中任何一种的患者,需要考虑急性闭角型青光眼风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acute angle-closure (AAC) glaucoma is a sight-threatening disease and can reportedly occur in association with various drugs. OBJECTIVE: To identify drugs that are associated with AAC glaucoma occurrence and evaluate the risk of AAC associated with each drug. DESIGN, SETTING, AND PARTICIPANTS: A case-crossover study was conducted using the Health Insurance Review and Assessment Service database, which contains medical information of the entire Korean population. Patients who were first diagnosed with AAC and treated between 2013 and 2019 were identified using diagnostic and procedure codes. All drugs that the study participants were prescribed as well as prescription dates during the period of 1 to 180 days before the onset of AAC were extracted from the database. For each patient, 1 to 30 days before onset was considered the hazard period, and 91 to 180 days before AAC onset was considered the control period. MAIN OUTCOMES AND MEASURES: Drugs associated with AAC and odds (calculated as odds ratios [ORs] with 95% CIs) of AAC development associated with each identified drug. RESULTS: A total of 949 drugs that were prescribed to 13 531 patients with AAC (mean [SD] age, 66.8 [10.6] years; 9585 [70.8%] female) during the period of 1 to 180 days before the onset of AAC were analyzed. A total of 61 drugs were found to be associated with AAC, among which sumatriptan (OR, 12.60 [95% CI, 4.13-38.44]) was associated with the highest odds of AAC development, followed by topiramate (OR, 5.10 [95% CI, 2.22-11.70]) and duloxetine (OR, 4.04 [95% CI, 2.95-5.54]). The median (IQR) period from prescription of the drug to the onset of AAC for the 61 drugs was 11.9 days (10.9-12.8). A number of drugs not previously considered to be associated with AAC, including lactulose (OR, 2.81 [95% CI, 1.72-4.61]) and metoclopramide (OR, 2.52 [95% CI, 1.95-3.25]), were identified. CONCLUSIONS AND RELEVANCE: Results of this case-crossover study suggest a need to consider AAC risk in patients taking any of the 61 drugs found to be associated with AAC.
引用
- Na KI, Park SP. Association of Drugs With Acute Angle Closure. JAMA Ophthalmol. 2022. PMID: 36136326. doi:10.1001/jamaophthalmol.2022.3723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。